Advanced search
Publication Cover
Pain Management Volume 7, 2017 - Issue 6
Submit an article Journal homepage
2,715
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Safety and Effectiveness of Once-Daily Hysingla Extended-Release Tablets in Patients with Baseline Depression or Anxiety

Louise Taber1 Arizona Research Center, Phoenix, AZ85023, USA
,
Ellie He2 Purdue Pharma LP, Stamford, CT06901, USACorrespondence[email protected]
&
Steven R Ripa2 Purdue Pharma LP, Stamford, CT06901, USA
Pages 473-488 | Received 27 Apr 2017, Accepted 03 Jul 2017, Published online: 27 Jul 2017

Figures & data

Table 1. Summary of demography and baseline characteristics of patients with and without active depression/anxiety

Table 2. Summary of medical history terms occurring in ≥10% of patients prior to enrollment by preferred term.

Table 3. Concomitant medications used to treat pain in ≥2% of patients with and without active depression/anxiety at baseline.

Table 4. Summary of patient disposition and reasons for study discontinuation among patients with and without active depression/anxiety at baseline.

Table 5. Opioid-related treatment-emergent adverse events in patients with depression/anxiety at baseline.

Figure 1. Mean ‘average pain over the last 24 h’ scores during the study in patients with and without depression/anxiety at baseline.

DT: Dose titration; HYD: Hydrocodone bitartrate; SE: Standard error.

Figure 1. Mean ‘average pain over the last 24 h’ scores during the study in patients with and without depression/anxiety at baseline.DT: Dose titration; HYD: Hydrocodone bitartrate; SE: Standard error.

Table 6. Brief pain inventory short form.

Figure 2. Mean ‘pain right now’ scores recorded daily immediately prior to dosing and at 12 h postdose and mean ‘Average Pain Over the Last 24 h’ score during the first 3 months of the maintenance period (dashed line) in patients (A) with and (B) without baseline depression/anxiety.

Error bars represent the standard deviation.

Figure 2. Mean ‘pain right now’ scores recorded daily immediately prior to dosing and at 12 h postdose and mean ‘Average Pain Over the Last 24 h’ score during the first 3 months of the maintenance period (dashed line) in patients (A) with and (B) without baseline depression/anxiety.Error bars represent the standard deviation.
Figure 3. Mean daily dose of hydrocodone bitartrate and supplemental opioid analgesics during the titration and maintenance periods in patients with and without depression/anxiety at baseline.

HYD: Hydrocodone bitartrate; SE: Standard error.

Figure 3. Mean daily dose of hydrocodone bitartrate and supplemental opioid analgesics during the titration and maintenance periods in patients with and without depression/anxiety at baseline.HYD: Hydrocodone bitartrate; SE: Standard error.
Figure 4. Hydrocodone bitartrate dose adjustments during the maintenance period in patients (A) with and (B) without depression/anxiety at baseline.

HYD: Hydrocodone bitartrate.

Figure 4. Hydrocodone bitartrate dose adjustments during the maintenance period in patients (A) with and (B) without depression/anxiety at baseline.HYD: Hydrocodone bitartrate.

Table 7. Treatment satisfaction questionnaire.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.